Literature DB >> 16691370

Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation.

Subarna A Khan1, Amy C Cook, Maya Kappil, Ursula Günthert, Ann F Chambers, Alan B Tuck, David T Denhardt.   

Abstract

Osteopontin (OPN) is a glycosylated, secreted phosphoprotein that functions both as a cell attachment and chemotactic factor. Elevated expression of OPN confers enhanced metastatic ability on transformed cells, suggesting that OPN may contribute to the malignant progression of tumors. Migration of mammary carcinoma cells is stimulated by OPN via interactions with integrins and CD44 cell surface receptors. We hypothesized that OPN modulates specific CD44 isoform expression to facilitate breast cancer cell migration. The 21NT tumorigenic human breast cancer cell line was examined for regulation of CD44 expression at both the mRNA and protein levels in response to an engineered increase in OPN expression under CMV promoter control. Significant up-regulation of CD44s isoform mRNA expression was observed, but no change in CD44v6, v8, v9 or v10 mRNA levels. While there were elevated levels of CD44s, v6 and v9 protein at the cell surface, at the level of total cellular protein only CD44s and v6 were markedly increased. This suggests that OPN can regulate CD44 expression at both transcriptional and post-transcriptional (both amount and localization of protein) levels. To validate the functional consequence of OPN regulation of CD44 expression, we demonstrate that OPN-mediated cell migration was reduced by exposure to a anti-pan CD44 antibody, and to anti-CD44v6 and anti-CD44v9 function-blocking antibodies. Our data provide evidence that in 21NT cells OPN enhances CD44s mRNA expression, increases cell surface expression of CD44 variant forms without a change in mRNA levels, and stimulates cell migration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691370     DOI: 10.1007/s10585-006-9007-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  47 in total

1.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

2.  Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential.

Authors:  M Culty; M Shizari; E W Thompson; C B Underhill
Journal:  J Cell Physiol       Date:  1994-08       Impact factor: 6.384

3.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

4.  Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.

Authors:  A B Tuck; D M Arsenault; F P O'Malley; C Hota; M C Ling; S M Wilson; A F Chambers
Journal:  Oncogene       Date:  1999-07-22       Impact factor: 9.867

5.  CD44 is not an adhesive receptor for osteopontin.

Authors:  L L Smith; B W Greenfield; A Aruffo; C M Giachelli
Journal:  J Cell Biochem       Date:  1999-04-01       Impact factor: 4.429

6.  Osteopontin: possible role in prostate cancer progression.

Authors:  G N Thalmann; R A Sikes; R E Devoll; J A Kiefer; R Markwalder; I Klima; C M Farach-Carson; U E Studer; L W Chung
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 7.  The functional and clinical roles of osteopontin in cancer and metastasis.

Authors:  K A Furger; R K Menon; A B Tuck; V H Bramwell; A F Chambers
Journal:  Curr Mol Med       Date:  2001-11       Impact factor: 2.222

8.  Osteopontin expression in a group of lymph node negative breast cancer patients.

Authors:  A B Tuck; F P O'Malley; H Singhal; J F Harris; K S Tonkin; N Kerkvliet; Z Saad; G S Doig; A F Chambers
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

9.  Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration.

Authors:  Toshiyuki Murai; Yoshihiro Miyazaki; Hitomi Nishinakamura; Kazuki N Sugahara; Takayuki Miyauchi; Yasushi Sako; Toshio Yanagida; Masayuki Miyasaka
Journal:  J Biol Chem       Date:  2003-11-17       Impact factor: 5.157

10.  Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin.

Authors:  Baoqian Zhu; Keiko Suzuki; Harvey A Goldberg; Susan R Rittling; David T Denhardt; Christopher A G McCulloch; Jaro Sodek
Journal:  J Cell Physiol       Date:  2004-01       Impact factor: 6.384

View more
  39 in total

Review 1.  Role of osteopontin in the pathophysiology of cancer.

Authors:  Lalita A Shevde; Rajeev S Samant
Journal:  Matrix Biol       Date:  2014-03-19       Impact factor: 11.583

2.  Role of tissue inhibitor of metalloproteinases-1 in the development of autoimmune lymphoproliferation.

Authors:  Elena Boggio; Manuela Indelicato; Elisabetta Orilieri; Riccardo Mesturini; Maria Clorinda Mazzarino; Maria Francesca Campagnoli; Ugo Ramenghi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  Haematologica       Date:  2010-06-30       Impact factor: 9.941

3.  Cancer Secretome May Influence BSP and DSP Expression in Human Salivary Gland Cells.

Authors:  Samantha Lynn Hamilton; Blake Ferando; Asha Sarah Eapen; Jennifer Chian Yu; Anita Rose Joy
Journal:  J Histochem Cytochem       Date:  2016-11-25       Impact factor: 2.479

4.  In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver.

Authors:  Allal Ouhtit; Zakaria Y Abd Elmageed; Mohamed E Abdraboh; Tong F Lioe; Madhwa H G Raj
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

Review 5.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 6.  Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.

Authors:  Akeila Bellahcène; Vincent Castronovo; Kalu U E Ogbureke; Larry W Fisher; Neal S Fedarko
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

7.  Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.

Authors:  Jennifer Sullivan; Laurel Blair; Amer Alnajar; Tamer Aziz; Chee Yuan Ng; Galina Chipitsyna; Qiaoke Gong; Agnes Witkiewicz; Georg F Weber; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

8.  Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma.

Authors:  Ali A Siddiqui; Elizabeth Jones; Darren Andrade; Apeksha Shah; Thomas E Kowalski; David E Loren; Galina Chipitsyna; Hwyda A Arafat
Journal:  J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 4.029

9.  Induction of osteopontin expression by nicotine and cigarette smoke in the pancreas and pancreatic ductal adenocarcinoma cells.

Authors:  Galina Chipitsyna; Qiaoke Gong; Rathai Anandanadesan; Amer Alnajar; Surinder K Batra; Uwe A Wittel; Diane M Cullen; Mohammed P Akhter; David T Denhardt; Charles J Yeo; Hwyda A Arafat
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

10.  Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta.

Authors:  Sylvia A Vetrone; Encarnacion Montecino-Rodriguez; Elena Kudryashova; Irina Kramerova; Eric P Hoffman; Scot D Liu; M Carrie Miceli; Melissa J Spencer
Journal:  J Clin Invest       Date:  2009-05-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.